RecruitingNCT07469709

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

A Platform for Assessing Personal Risk of Developing or Recurring of Cancer: Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring of Subclinical Recurrences With Therapeutic Impact

Sponsor

Fondazione del Piemonte per l'Oncologia

Enrollment

850 participants

Start Date

Feb 1, 2024

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Ovarian Cancer Colo-rectal Cancer Melanoma (Skin Cancer)Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)

Summary

The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase. The PRO-ACTIVE study includes the following activities: * WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors * WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences * WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors * WP4: Study of the tumor microenvironment for recurrence prediction

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is collecting biological, genetic, and health data from cancer patients to better understand the personal risk factors for cancer and how to monitor patients non-invasively over time. The goal is to use this information to improve cancer risk assessment and monitoring tools. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with one of the following: breast cancer (including those eligible for BRCA genetic testing or with lobular breast cancer), radically resected colon cancer (stage III or with vascular invasion), ovarian carcinoma, metastatic melanoma, or stage IIB–IIIA non-small cell lung cancer **You may NOT be eligible if...** - You are under 18 years old - You are unwilling or unable to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.